Tumor Markers: Relationship between Clinical Pathology and Molecular Diagnostics/Immunohistochemistry
This presentation will highlight the use of tumor markers in serum chemistry, and their relationship to the diagnosis and monitoring of patients with malignant disease. Tumor markers are molecules occurring in blood or tissue that are associated with cancer, and whose measurement or identification is useful in patient diagnosis or clinical management. The ideal marker would be a “blood test” for cancer, in which a positive result would occur only in patients with malignancy, would correlate with stage and response to treatment, and that is easily and reproducibly measured. No tumor marker now available has met this ideal, but development and discovery continues in the use of these markers for clinical diagnosis. This presentation will explore the use of common markers such as CA-125, Carcinoembryonic Antigen (CEA), Alpha-Fetoprotein (AFP), CA 72.4, CA 15.3, CA19.9, Prostate Specific Antigen (PSA), and a variety of other enzymes and proteins now in use for the diagnosis and monitoring of malignancy. In addition, future serum tumor markers and the use of gene expression profiles and other information from circulating tumor cells (CTCs) will also be discussed.
Learning Objectives
- An overview of current serum tumors markers, their different classifications, and their use in disease monitoring.
- The usage of tumor markers in patient diagnosis and management, in both clinical medicine and immunohistochemistry will be discussed.
- A review of future developments in tumor markers and diagnostic methods, including DNA isolation and gene expression profiles of circulating tumor cells.
About the presenter
Dr. Thomas Haas is an attending Pathologist and Director of Molecular Pathology at Mercy Health Systems, Janesville, Wisconsin. He received his Doctor of Osteopathic Medicine from Des Moines University. His daily responsibilities involve anatomic, cytologic, and clinical pathology in a community hospital and system reference laboratory, with participation in tumor board and medical education conferences. His areas of interest include the development of immunohistochemistry panels for tumor diagnosis, molecular pathology, and histotechnology education for the National Society for Histotechnology (NSH). Dr. Haas is board certified in Anatomic and Clinical Pathology.
Die Inhalte des Knowledge Pathway von Leica Biosystems unterliegen den Nutzungsbedingungen der Website von Leica Biosystems, die hier eingesehen werden können: Rechtlicher Hinweis. Der Inhalt, einschließlich der Webinare, Schulungspräsentationen und ähnlicher Materialien, soll allgemeine Informationen zu bestimmten Themen liefern, die für medizinische Fachkräfte von Interesse sind. Er soll explizit nicht der medizinischen, behördlichen oder rechtlichen Beratung dienen und kann diese auch nicht ersetzen. Die Ansichten und Meinungen, die in Inhalten Dritter zum Ausdruck gebracht werden, spiegeln die persönlichen Auffassungen der Sprecher/Autoren wider und decken sich nicht notwendigerweise mit denen von Leica Biosystems, seinen Mitarbeitern oder Vertretern. Jegliche in den Inhalten enthaltene Links, die auf Quellen oder Inhalte Dritter verweisen, werden lediglich aus Gründen Ihrer Annehmlichkeit zur Verfügung gestellt.
Vor dem Gebrauch sollten die Produktinformationen, Beilagen und Bedienungsanleitungen der jeweiligen Medikamente und Geräte konsultiert werden.
Copyright © 2024 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.